Press Releases

Bora Biologics Receives 2025 CDMO Leadership Award

Bora Biologics has been recognized at the 2025 CDMO Leadership Awards, presented by Outsourced Pharma. The company was named a winner in the Biologics – Global category.

The CDMO Leadership Awards recognize top‑performing development and manufacturing service providers based on global client feedback. Award criteria span key areas including facilities, innovation, technical expertise, service quality, and manufacturing capabilities, making the program one of the industry’s most trusted benchmarks for sponsor satisfaction.

“We are honored to receive this recognition and sincerely thank our clients and partners for their continued trust in Bora Biologics,” said Marc Goemans, Chief Commercial Officer. “This award reflects our unwavering commitment to GMP excellence, operational rigor, and delivering high‑quality biologics that support our partners’ success.”

“We are proud to introduce the 2025 CDMO Leadership Awards winners to the outsourcing community and to provide drug sponsors with a meaningful, data‑driven resource for selecting the right development and manufacturing partners,” said Louis Garguilo, Chief Editor of Outsourced Pharma. “The enhanced scoring methodology and expanded categories make this year’s awards an even more valuable distinction for CDMOs.”

Bora Biologics continues to strengthen its GMP manufacturing capabilities and infrastructure to meet the evolving needs of global biopharmaceutical partners, with a continued focus on quality, reliability, and long‑term collaboration.

About Bora Biologics
Bora Biologics is a global CDMO offering agile, comprehensive end-to-end solutions for biopharma companies worldwide. With a proven track record of over 100 successful cGMP manufacturing batches, Bora Biologics leverages its state-of-the-art, FDA-registered facility in the U.S. and deep expertise in biologics development and manufacturing—including its own FDA-licensed and Health Canada approved product—to enhance time and cost efficiencies while ensuring effective pathways to market for its clients. Bora Biologics combines innovative early-phase development and late-stage manufacturing capabilities with the expertise and reputation of Bora Pharmaceuticals for flexible and scalable fill/finish services, including stability testing and final packaging of clinical and commercial products.

Media Contact
media@borabiologics.com

CDMO Inquiries
bd@borabiologics.com

Filter

Bora Biologics

the logical choice

Join the ranks of biopharma pioneers who trust us.
Explore how we minimize risks and accelerate your success.

Partner with us

Client-Centric

100% commitment to supporting your success

We have been the client, bringing multiple biologics from IND to BLA. Your needs and goals are at the forefront of our approach. By involving you in every step of the process, we ensure transparency and alignment, reducing the likelihood of misunderstandings and ensuring the outcome meets your expectations.

Experience

14 years developing & manufacturing biologics

We have honed our ability to navigate complexities. Our track record from concept to commercialization means we can apply best practices and lessons learned, ensuring smoother project execution.

Expertise

125 seasoned scientists & regulatory professionals

Our team exudes deep knowledge and specialized skills. This expertise allows us to foresee potential challenges and implement proactive solutions, reducing the likelihood of setbacks.

Commercial-Ready

US FDA registered GMP manufacturing facility

We focus on delivering solutions that are ready for market. With clinical to commercial scale facilities consistently meeting compliance standards, we ensure your project is primed for success, minimizing the risk of costly revisions or delays.

Allied

access to global CDMO resources

Our partnership with Bora Pharmaceuticals provides additional resources and insights. This network enables us to leverage shared knowledge and expertise, further mitigating risks and accelerating the overall success of your project.